Description

Vertex Pharmaceuticals Acquisition Alert: The $10 Billion Crinetics Deal That Could Redefine Growth!

Vertex Pharmaceuticals moved decisively into specialty endocrinology by agreeing to acquire Crinetics Pharmaceuticals (NASDAQ:CRNX) for $85 per share in cash, implying about $10 billion of equity value and roughly $8.8 billion net of estimated cash acquired. The agreement, announced in early July 2026, comes as Vertex looks to broaden a business still heavily anchored in cystic fibrosis, where it generated most of its $12 billion 2025 revenue. Crinetics brings PALSONIFY, an FDA-approved once-daily oral acromegaly therapy launched in October 2025, and Atumelnant, a once-daily oral ACTH receptor antagonist in Phase III for congenital adrenal hyperplasia and Phase II for ACTH-dependent Cushing’s syndrome. Vertex says the two lead assets could exceed $5 billion in combined peak annual sales, while the transaction could close in the third quarter of 2026, subject to shareholder and regulatory approvals. It also gives Vertex a fifth commercial pillar beyond CF, heme, pain and renal programs.